TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT06220773: A Randomized, Double-blind, Multi-center, Phase 3 Study to Evaluate the Efficacy and Safety of BR1019A and BR1019B Combination Therapy in Patients With Essential Hypertension and Type 2 Diabetes Mellitus

Sponsor: Boryung Pharmaceutical Co., Ltd · Phase: PHASE3 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 276 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$15,086,080

Rescue Site Savings

+$9,947,384

Unlock Full NCT06220773 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06220773 Rescue Dossier →